黑料网

Grimm MO, Mett J, Hartmann T (2016) The Impact of Vitamin E and Other Fat-Soluble Vitamins on Alzheimer´ s Disease. International Journal of Molecular Sciences 17: 1785.

Hori K, Konishi K, Tomioka H, Tani M, Minegishi G (2012) Reviews: Serum Anticholinergic Activity: A Biomarker for Rapid Progression of Alzheimer’s Disease. Autacoids S4 1: 2161-0479.

Hori K, Konishi K, Hosoi M, Tomioka H, Tani M,et al. (2016) Mini Review: Anticholinergic Activity as a Behavioral Pathology of Lewy Body Disease and Proposal of the Concept of “Anticholinergic Spectrum Disorders”. Parkinson’s Disease 22.

Mushtaq R, Pinto C, Tarfarosh SF, Hussain A, Shoib S, et al. (2016) A Comparison of the Behavioral and Psychological Symptoms of Dementia (BPSD) in Early-Onset and Late-Onset Alzheimer’s Disease-A Study from South East Asia (Kashmir, India). Cureus 8.

Nomura J, Hosoi T, Kaneko M, Ozawa K, Nishi A, Nomura Y (2016) Neuroprotection by Endoplasmic Reticulum Stress-Induced HRD1 and Chaperones: Possible Therapeutic Targets for Alzheimer’s and Parkinson’s Disease. Medical Sciences 4: 14.

Takata K, Kitamura Y (2012) Molecular approaches to the treatment, prophylaxis, and diagnosis of Alzheimer’s disease: Tangle formation, amyloid-β, and microglia in Alzheimer’s disease. Journal of pharmacological sciences 118: 331-337.

Bhattacharjee P, Bhattacharyya D (2015) An Enzyme from Aristolochia indica Destabilizes Fibrin-β Amyloid Co-Aggregate: Implication in Cerebrovascular Diseases. PloS one 10: e0141986.

Blum K, Downs BW, Dushaj K, Li M, Braverman ER, et al. (2016) THE BENEFITS OF CUSTOMIZED DNA DIRECTED NUTRITION TO BALANCE THE BRAIN REWARD CIRCUITRY AND REDUCE ADDICTIVE BEHAVIORS. Precision medicine 1: 18.

Blum K, Femino J, Teitelbaum S, Giordano J, Oscar-Berman M, Gold M (2013) Molecular Neurobiology of Recovery with the Twelve Steps. InMolecular Neurobiology of Addiction Recovery: 11-82.

Ahmed Saadani Hassani MD, Marston BJ, Kaplan JE (2015) HHS Public Access. J Acquir Immune Defic Syndr 68: S257-S269.

Blum K, Febo M, D Badgaiyan R, R Braverman E, Dushaj K, et al. (2016) Neuronutrient Amino-Acid Therapy Protects Against Reward Deficiency Syndrome: Dopaminergic Key to Homeostasis and Neuroplasticity. Current Pharmaceutical Design 22: 5837-5854.

Uddin MS, Al Mamun A, Sarwar MS, Chaity NH, Haque A, Akter N, Amran MS. Medicine that Causes Memory Loss: Risk of Neurocognitive Disorders.

Vitali M, Napolitano C, Berman MO, Minuto SF, Battagliese G, et al. (2016) Neurophysiological Measures and Alcohol Use Disorder (AUD): Hypothesizing Links between Clinical Severity Index and Molecular Neurobiological Patterns. Journal of addiction research & therapy 5.

Blum K, Badgaiyan R, Agan G, Fratantonio J, Gold MS (2014) Reward Deficiency Syndrome (RDS): Is there a Solution?. Journal of Alcoholism & Drug Dependence.

Blum K, Febo M, Fried L, Li M, Dushaj K, et al. (2017) Hypothesizing That Neuropharmacological and Neuroimaging Studies of Glutaminergic-Dopaminergic Optimization Complex (KB220Z) Are Associated With “Dopamine Homeostasis” in Reward Deficiency Syndrome (RDS). Substance Use & Misuse 52: 535-547.

Modestino EJ, Blum K, Oscar-Berman M, Gold MS, Duane DD, et al. (2015) Reward Deficiency Syndrome: Attentional/Arousal Subtypes, Limitations of Current Diagnostic Nosology, and Future Research. Journal of reward deficiency syndrome 1: 6.

Filipiak-Florkiewicz A, Topolska K, Florkiewicz A, Cie脙聟芒聙潞lik E. Are Environmental Contaminants Responsible for ‘Globesity’?.

Blum K, Thanos PK, Oscar-Berman M, Febo M, Baron D, et al. (2015) Dopamine in the Brain: Hypothesizing Surfeit or Deficit Links to Reward and Addiction. Journal of reward deficiency syndrome 1: 95.

Canales JJ (2014) The Trace of Non-classical Biogenic Amines: A New Road to Addiction Recovery. J Addict Res Ther 4: 166.